[go: up one dir, main page]

MX2019008787A - Sal de etano-sulfonato del derivado de quinolina. - Google Patents

Sal de etano-sulfonato del derivado de quinolina.

Info

Publication number
MX2019008787A
MX2019008787A MX2019008787A MX2019008787A MX2019008787A MX 2019008787 A MX2019008787 A MX 2019008787A MX 2019008787 A MX2019008787 A MX 2019008787A MX 2019008787 A MX2019008787 A MX 2019008787A MX 2019008787 A MX2019008787 A MX 2019008787A
Authority
MX
Mexico
Prior art keywords
ethane
quinoline derivative
sulphonate salt
sulphonate
salt
Prior art date
Application number
MX2019008787A
Other languages
English (en)
Other versions
MX379140B (es
Inventor
Nekado Takahiro
Kijima Hideomi
Ono Shizuka
Nishiyama Toshihiko
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2019008787A publication Critical patent/MX2019008787A/es
Publication of MX379140B publication Critical patent/MX379140B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con el etanosulfonato de N-{5-[(6,7-dimetoxi-4-quinolinil)oxi]-2-piridinil}-2, 5-dioxo-1-fenil-1, 2, 5, 6, 7, 8-hexahidro-3-quinolincarboxamida, el cual tiene una actividad inhibidora de Axl y es útil como agente para prevenir y/o tratar enfermedades inmunes, cáncer y similares, un cristal del mismo y una composición farmacéutica del mismo.
MX2019008787A 2017-01-26 2018-01-25 Sal de etano-sulfonato del derivado de quinolina. MX379140B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017011835 2017-01-26
PCT/JP2018/002250 WO2018139527A1 (ja) 2017-01-26 2018-01-25 キノリン誘導体のエタンスルホン酸塩

Publications (2)

Publication Number Publication Date
MX2019008787A true MX2019008787A (es) 2019-09-11
MX379140B MX379140B (es) 2025-03-10

Family

ID=62979439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008787A MX379140B (es) 2017-01-26 2018-01-25 Sal de etano-sulfonato del derivado de quinolina.

Country Status (21)

Country Link
US (1) US10836747B2 (es)
EP (1) EP3575293B1 (es)
JP (1) JP6605763B2 (es)
KR (1) KR102571911B1 (es)
CN (2) CN110225908A (es)
AU (1) AU2018211801B2 (es)
CA (1) CA3051605C (es)
DK (1) DK3575293T3 (es)
ES (1) ES2872923T3 (es)
HU (1) HUE054883T2 (es)
IL (1) IL268221B (es)
MX (1) MX379140B (es)
MY (1) MY196680A (es)
PH (1) PH12019501693A1 (es)
PL (1) PL3575293T3 (es)
PT (1) PT3575293T (es)
RU (1) RU2019123279A (es)
SG (1) SG11201906819VA (es)
TW (1) TWI779007B (es)
WO (1) WO2018139527A1 (es)
ZA (1) ZA201904895B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019039525A1 (ja) * 2017-08-23 2019-02-28 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
KR20250053959A (ko) * 2022-08-30 2025-04-22 트랜스테라 사이언시즈 (난징), 인크. 퀴놀린 유도체 억제제의 결정형 및 이의 제조 방법과 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6428234B1 (en) * 2000-01-07 2002-08-06 Closure Medical Corporation Adhesive applicator tips with improved flow properties
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
ATE528002T1 (de) 2006-05-19 2011-10-15 Bayer Pharma AG Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
WO2007146824A2 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
KR101325237B1 (ko) 2008-04-16 2013-11-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ａｘｌ 키나아제 억제제인 퀴놀린 유도체
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
CA2738583A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
JP2010178651A (ja) 2009-02-04 2010-08-19 Eisai R & D Management Co Ltd Ｈｇｆｒ阻害物質の作用検定方法
WO2012011548A1 (ja) 2010-07-23 2012-01-26 国立大学法人 東京大学 含窒素複素環誘導体
JP5791412B2 (ja) 2010-07-26 2015-10-07 日本碍子株式会社 セラミックヒーター
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
JP2013074633A (ja) 2011-09-26 2013-04-22 Oki Electric Ind Co Ltd スイッチング電源装置及び現金自動預け払い装置
CN103958497B (zh) 2011-11-14 2017-09-01 亚尼塔公司 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物

Also Published As

Publication number Publication date
PL3575293T3 (pl) 2021-09-06
US10836747B2 (en) 2020-11-17
WO2018139527A1 (ja) 2018-08-02
DK3575293T3 (da) 2021-04-26
CN119707932A (zh) 2025-03-28
RU2019123279A (ru) 2021-02-26
PT3575293T (pt) 2021-05-25
EP3575293A4 (en) 2019-12-04
CN110225908A (zh) 2019-09-10
KR20190111035A (ko) 2019-10-01
BR112019015352A2 (pt) 2020-03-10
KR102571911B1 (ko) 2023-08-28
AU2018211801B2 (en) 2021-07-08
EP3575293B1 (en) 2021-03-10
NZ755665A (en) 2024-07-26
IL268221A (en) 2019-09-26
JP6605763B2 (ja) 2019-11-13
PH12019501693A1 (en) 2020-06-15
TW201833099A (zh) 2018-09-16
ES2872923T3 (es) 2021-11-03
US20190389837A1 (en) 2019-12-26
ZA201904895B (en) 2025-10-29
HUE054883T2 (hu) 2021-10-28
MX379140B (es) 2025-03-10
WO2018139527A9 (ja) 2018-09-20
RU2019123279A3 (es) 2021-03-31
MY196680A (en) 2023-04-29
EP3575293A1 (en) 2019-12-04
IL268221B (en) 2022-03-01
SG11201906819VA (en) 2019-08-27
AU2018211801A1 (en) 2019-08-15
CA3051605C (en) 2024-06-25
JPWO2018139527A1 (ja) 2019-06-27
TWI779007B (zh) 2022-10-01
CA3051605A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2019000844A1 (es) Compuesto de piridina.
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
AR101740A1 (es) Terapia de combinación y composiciones
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
PH12017502363A1 (en) Brk inhibitory compound
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
EA201990400A1 (ru) Соединения и композиции и их применение
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX376183B (es) Composiciones para el tratamiento de rosacea.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2019008787A (es) Sal de etano-sulfonato del derivado de quinolina.
MX2017001629A (es) Anticuerpo anti-orai1.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
MX2019004200A (es) Terapia de combinacion.
CL2017000988A1 (es) Proceso de síntesis de hidroxi-triacilgliceroles y usos de los mismos para la prevención y el tratamiento de enfermedades